Metabolic dysfunction-associated fatty liver disease: a new clearer nomenclature with positive diagnostic criteria
|Journal||Volume 83 - 2020|
|Issue||Fasc.4 - Editorial|
|Author(s)||N. Lanthier 1 2, T. Vanuytsel 3 4|
VIEW FREE PDF
(1) Service d’Hépato-gastroentérologie, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium ;
(2) Laboratory of Gastroenterology and Hepatology, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, Belgium
(3) Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
(4) Translational Research in Gastrointestinal Diseases (TARGID), KU Leuven, Leuven, Belgium.
Don’t say NAFLD anymore but MAFLD (“metabolic” instead of “non-alcoholic”) (1,2) ! This liver disease, which is the most frequent cause of elevated liver tests in our country, finally has an appropriate name. Until recently, MAFLD was a diagnosis of exclusion, in a patient with more than 5% steatotic hepatocytes at the liver histology and after having ruled out the consumption of alcoholic beverages but also other rarer causes (such as viral hepatitis infection, drugs, auto-immune disorders...). The different non-invasive techniques for the detection of steatosis described in our guidance document (3) are now possible for this new positive diagnosis of MAFLD (Table).
Keywords: MAFLD, NASH, steatosis, ALD, histology, diagnosis.
© Acta Gastro-Enterologica Belgica.